From the longitudinal study of a cohort of HIV-positive patients, we report the case of a patient who initially harbored the Epstein-Barr virus (EBV) type 1 and subsequently developed an EBV-2-associated non-Hodgkin's B lymphoma a few years after an EBV-2 reactivation, or an exogenous reactivation, in the blood. At the time of diagnosis of hepatic lymphoma, the blood and the throat harbored high levels of the EBV-1 dominant strain. Sequence analysis of EBNA-2 gene revealed that: (1) type 2 EBV detected during reactivation and then in hepatic tumor was very likely to be the same strain and was mostly identical to the EBV prototype AG876; (2) type 1 virus conserved the same mutations during all the follow-up. These results suggest that EBV-2 might be associated with lymphomatogenesis and that a transient reactivation could lead to the development of an EBV-associated disease.
Introduction
Epstein-Barr virus (EBV) is a gammaherpesvirus that infects more than 90% of the human population. In most individuals, the virus persists as an asymptomatic infection characterized by virus shedding from lytically infected cells in the oropharynx and by the presence of latently infected cells within the circulating B lymphocyte pool. EBV is the causative agent of acute infectious mononucleosis and is associated with a number of malignancies in both immunocompetent and immunocompromised individuals. In human immunodeficiency virus (HIV)-infected individuals and in iatrogenically immunosuppressed patients, a wide spectrum of disorders, such as B cell non-Hodgkin's lymphoma (NHL) and oral hairy leukoplakia (OHL), arise as a consequence of changes in the EBV-host balance.
EBV can be distinguished into two major families of isolates, referred to as type 1 (EBV-1) and type 2 (EBV-2), based on allelic polymorphisms in the latent genes encoding the four nuclear antigens EBNA2, 3A, 3B and 3C. 1 The susceptibility of normal virus carriers and immunosuppressed patients to infection with more than one EBV type remains to be elucidated. In the Caucasian population, most healthy carriers seem to harbor a single EBV strain which persists over time and is dominant both in the blood and in the throat. 2 While most individuals in Western countries carry EBV-1, an EBV-2 predominance was previously thought to be limited to Central Africa and New Guinea. In more recent studies in HIV-positive individuals, we and others have shown that: (1) this population was highly infected by EBV-2 (up to 20% vs 3-5% in Caucasian controls); (2) the dominant strain was mostly retained in both viral reservoirs; (3) changes in the dominant EBV type could occur in the same individual. [3] [4] [5] However, although multiple EBV infections with different variants of the same type, or coinfection with type 1 and type 2 strains, have been detected in the blood as well as in the throat of immunocompromised patients, 6 there is no evidence that EBV-1 and EBV-2 may play different oncogenic roles in vivo.
From a follow-up study of a cohort of 33 HIV-positive patients, 5 we report, in one of the patients studied, the unusual development of an EBV-2 hepatic B cell non-Hodgkin's lymphoma following EBV-2 reactivation, or superinfection, while the peripheral blood and saliva again harbored the EBV-1 dominant strain.
Case report
A French Caucasian homosexual patient with a documented HIV-1 infection since 1985 was found to harbor the EBV-1 dominant viral strain in his blood. During the follow-up, in 1990, a molecular analysis showed the emergence of the EBV-2 type in the B cell population. In 1993, this patient was diagnosed with an acquired immunodeficiency syndrome (AIDS) because of a pneumocystosis (with a number of T CD4 + cells of 100 × 10 6 /1). In 1994, a Kaposi's sarcoma with cutaneous and oropharyngeal lesions was discovered. At the end of 1995, a liver tumor was diagnosed. On histological analysis of the biopsy a diffuse large cell lymphoma replaced the normal architecture, with a diffuse infiltrate of large lymphoid cells. The nuclei were mostly round with vesicular chromatin and membrane-bound nucleoli. By immunohistochemistry the neoplastic proliferation expressed various pan-B markers such as CD20 and CD79a but lacked expression of CD3, CD5 and CD10. A diagnosis of diffuse large B cell lymphoma (Real classification 7 ) or centroblastic lymphoma (updated Kiel classification 8 ) was stressed ( Figure 1 ). No additional lymphomatous localization was detected at this time and during the follow-up. The patient died in 1997 of an invasive aspergillosis during anti-tumoral chemotherapy.
The EBV genome was detected in the liver biopsy sample. In order to investigate EBV type and variants, we developed a PCR technique that allowed the amplification of the entire EBNA-2 gene. To increase the sensitivity of the method, we had to perform the genotyping with a semi-nested PCR within the N-terminal domain.
We found that the hepatic lymphomatous mass was predominantly infected by EBV-2 ( Figure 2 ). The sequencing of 680 bp (nucleotide 1590-2270 as referred to the AG876 prototype) revealed that this EBNA-2 region was conserved, as compared to the prototype AG876, since no, or very little,
Figure 1
Histological analysis of the liver biopsy. The biopsy was bouin fixed, paraffin embedded and hematoxylin eosin, Giemsa and periodic acid schiff stained. A diffuse large cell lymphoma replaces the normal architecture with a diffuse infiltrate of large lymphoid cells.
Figure 2
PCR analysis of the EBV strain carried in the liver lymphoma biopsy. For the genotyping, samples were initially amplified by the 5Ј primer DM1 (5Ј CCTACATTCTATCTTGCGTTAC; B95-8 coordinates 48507 to 48528) and the 3Ј primer DM2 (5Ј-AGAGGTCGTTGGTTACAT; B95-8 coordinates 49997 to 49980) which span the entire EBNA-2 gene. DNA (1 g) was denatured at 94°C for 6 min and amplification was carried out by 35 cycles of denaturation at 94°C for 60 s, annealing at 58°C for 60 s and extension at 65°C for 60 s in a 2400 Thermal Cycler (Perkin-Elmer Cetus, Foster City, CA, USA), using the 'Expand Long Template PCR System' (Boehringer Mannheim, Germany) for the reaction mixture. A seminested PCR was then performed using DM1 as 5Ј primer and 3Ј primer BM2 (5Ј-GGTGCTGCTGGTGGTGGCAAT; B95-8 coordinates 49405 to 49384). 2 l of amplified products were denatured at 94°C for 3 min and amplification was carried out by 30 cycles of denaturation at 94°C for 30 s, annealing at 58°C for 30 s and extension at 72°C for 30 s in the 2400 Thermal Cycler. These two PCR allowed the amplification of both EBV types 1 and 2. Hybridization with either 32 P-labelled probe MB3 (5Ј-CGCATGCATCTCCCTGTCTT; B95-8 coordinates 49240 to 49259) or 32 P-labelled probe MB4 (5Ј-CCACAAAGGCTCACACTAGG; AG876 coordinates 2139 to 2158) allowed the discrimination between type 1 and type 2, respectively. variation was observed. Using a specific PCR, 9 we showed that this tumor specimen was not infected by HHV-8.
To determine whether EBV type 2 was also present in other sites, the patient was sampled for more than a year and PCR tests were performed serially (Table 1) . EBV viral load was estimated by a semiquantitative PCR with amplification in the BamHI C region. 10 Throughout the whole follow-up study, we observed high levels of EBV DNA in both cellular and plasma samples, as well as in the saliva. These results are consistent with an EBV reactivation in the blood and intensive viral replication in the oropharynx. The detection of EBV genome in the plasma, since it is not observed in healthy individuals, 11 suggests an EBV-associated disorder.
As regards the genotyping, the dominant type 1 alone was detected by semi-nested PCR in all the samples (Table 1) . In order to determine if this dominant EBV-1 was the same strain as before EBV-2 reactivated, and was the only type detectable in the blood, EBNA-2 PCR products were directly sequenced.
The sequence data ( Table 2) show nucleotide and predicted amino acid changes relative to the type 1 EBNA-2 sequence of the B95-8 reference strain. A similar pattern of results was obtained for some mutations which seemed to be conserved over time, while others seemed to arise during the course of the disease. So, nucleotide mismatches at positions 48628, 48905, 48990/1, 48998, 49095, 49211, 49236, 49303 were constantly detected. These mutations displayed changes affecting five amino acids. In return, mutations at positions 48541, 48554 and 48643 were observed in a single sample and it is difficult to affirm whether there are really new mutations. However, the nucleotide mismatch at position 48591 was observed in two samples obtained in the meantime at 3 months, once in the lymphoblastoid cell line (LCL) and once in peripheral blood mononuclear cells (PBMC), which suggests that mutation could naturally occur during the course of the disease. The fact that this mutation was detectable in the LCL and not in the PBMC sampled the same day, could suggest the presence of coresident variants in B lymphocytes. EBV viral load was estimated by comparing the autoradiographic signals of amplified BamHI C products to the signals obtained using the Namalwa cell line, which contains two copies of EBV DNA per cell, as standard reference. Serial 10-fold dilutions were performed to obtain a range from 1 g to 1 pg of DNA (300 000 copies to 0.3 copies). The number of copies was estimated per g DNA for peripheral blood mononuclear cells (PBMC) and saliva, and per 40 l plasma. Genotyping was performed as described in Figure  2 . a Lymphoblastoid cell lines (LCL) previously described by Buisson et al. 5 ND, not done. Samples, as well as B95-8 reference cell line, were amplified as described in Figure 2 . Double-stranded DNA sequencing was performed by the dideoxy chain termination method and automated analysis (Applied Biosystems, Foster City, CA, USA 373A DNA sequencer). Nucleotide and amino acid changes by comparison with the B95-8 sequence are shown in darker shading; their positions are identified by the B95-8 coordinates and EBNA2 codon numbers given at the top of the table.
a Uninterpretable.
Some of the mutations we observed have already been reported. Similar mutations at codon positions 163 and 165 have been observed in some pathologies. [12] [13] [14] [15] As these sequence mismatches are also shared by EBV-1 isolates from New Guinea, 16 it seems that these mutations are not significant for a particular disease or geographical distribution. Unlike these previous mutations, an amino acid substitution in codon 42 and a nucleotide mutation in codon 134 were described in two reports only. 12, 15 Of interest, in Yao's study, 15 these substitutions were only detected in a recombinant virus which appeared to be type 1 at the EBNA-2 locus and type 2 at the EBNA-3 loci. This recombinant virus also carried mutations at codon positions 163, 165 and 198. Furthermore, mutations at positions 48628, 49990, 48998 and 48211 have been described by Walling et al 12 in the MT1444 EBNA2 prototype obtained from an OHL lesion.
On the contrary, the nucleotide mutations 49236 and 49303 have not been described by others as yet. Since we had already detected the mutation 49303 in another HIV-positive individual, 5 it is not excluded that these changes could characterize strains with a common geographic origin.
Generally, the sequence changes we observed in the EBNA-2 gene would not disrupt the known EBNA-2 functional domains involved in transcriptional activation and B lymphocyte growth transformation. 17 However, the substitution of asparagine at codon 42 is located within the HLA-B51/A2 cytotoxic T lymphocyte epitope sequence, specific to EBV type 1, and could alter the immune response (for review see Ref. 18 ). Interestingly, our patient was HLA A11; B51, B44.
Discussion
In this study, we report the case of an HIV-1-positive individual initially predominantly infected by EBV-1. Following either a reactivation or an exogenous superinfection with EBV-2, which then became dominant, this patient developed an EBV-2 lymphoma strictly located in the liver. It is noteworthy that at the time of diagnosis of the malignant process, the EBV dominant type in both the blood and the throat was EBV-1. This suggests that the EBV-2 strain detected in the liver was unlikely to be due to infiltrating B lymphocytes. Previous data have shown that a multiple EBV infection, either with different strains of the same type or with viruses of different types, is coresident in main viral reservoirs. We observed that a tumor lymphoma mass might retain a viral type different to that dominant in the B circulating and oropharyngeal cells. In the patient studied, the EBV-1 variants still detected after the diagnosis of lymphoma were mostly identical to those detected before the EBV-2 reactivation.
This observation suggests the coexistence of the two types (EBV-1 and EBV-2) before and after EBV-2 multiplication increased. So, it is likely that the EBV-2-associated lymphoma arose when this EBV type was dominant in the blood. Furthermore, as some of the mutations we detected have been observed in intertypic recombinants, 15 we cannot exclude that our HIV-positive patient also harbored a type 1/type 2 recombinant virus. It would be of interest to sequence the EBNA-3 region.
Primary liver lymphomas are uncommon in the general population but may be observed after a liver transplantation. 19, 20 A few cases only have been reported in the HIVinfected population. 21 Furthermore, although infection by either EBV type 1 and/or type 2 has been described in NHL biopsies of HIV-positive individuals in some reports, 22-24 type 2 alone was not detected in any of the 12 EBV-associated NHL tested in a recent study. 25 However, all these studies have only typed the EBV involved in the tumor biopsy and no information was available concerning the EBV dominant type at the other viral sites. In our study, the follow-up of the dominant EBV strain in the blood and in the throat lead us to highlight an EBV-2 reactivation which preceded by 5 years the development of the EBV-2 associated tumor. So, whatever the EBV-2 true incidence in lymphoma tissue, changes observed in the dominant EBV type in blood, as well as the detection of EBV-2 in hepatic lymphoma while the other compartments harbored high levels of EBV-1 strain at that moment, seem to be of particular interest. Therefore, a previous EBV-2 reactivation, or an exogenous superinfection, could be linked to the development of an EBV-associated tumor. Also, the present work confirms the coexistence of EBV multiple infection in the circulating B cell pool; it shows, moreover, that a tumor lymphoma may retain a viral type different from the resident dominant EBV type in the blood and the throat.
